

Anti-VEGFR2 Antibodies

Drug Name	***0036
Description	A fully human monoclonal antibody targeting VEGFR2 is in phase I clinical trials for the treatment of solid tumors.
Target	Vascular Endothelial Growth Factor Receptor-2 (VEGFR2)
Drug Modality	Antibody
Indication	Solid Tumor
Product Category	Cancer Immunotherapy
Mechanism of Action	Anti-VEGFR-2
Status	Phase I
Patent	Granted

More Detail Available Upon Request

We look forward to hearing from you.